|
Ergomed PLC - Guildford, England-based service provider to the biopharmaceutical industry - Reports strong start to 2022, with a robust order book and strong sales momentum. Cites the resilience of its services-based business model for this. Notes continued organic growth, with year-to-date revenue increasing in line with prior trends. Expects to deliver trade growth in line with current market expectations.
Separately, at the company's annual general meeting, 22% of shareholders voted against resolution five, to reappoint Michael Spiteri. 17% of shareholders also voted against resolution four, to reappoint Mark Enyedy.
Current stock price: 1,004.00 pence, down 2.9% in London
12-month change: down 23%
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
